Ardelyx Inc (ARDX) Return on Assets ROA from the second quarter of 2026 to second quarter of 2025 and for the year 2026, Average High and Low, Fundamental Ratios from Jun 30 2026 to Jun 30 2025 - CSIMarket
Ardelyx Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period
Return on Assets, Quarterly Results, Trends, Rankings, Statistics
What is Ardelyx Inc 's ROA in the second quarter of 2026?
Ardelyx Inc recorded a cumulative net loss of $-56 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -10.79%.
However, within the Healthcare sector 297 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 3264, from total ROA ranking in the first quarter of 2026 at 3863.
In an era where healthcare innovation is paramount, Ardelyx, Inc. a biopharmaceutical entity based in Waltham, Massachusetts, has recently made strides in addressing a critical gastrointestinal disorder—irritable bowel syndrome with constipation (IBS-C)—through the publication of a comprehensive review article. This piece, featured in Clinical and Experimental Gastroenterology , highlights not only the significant patient burden associated with IBS-C but also the evolving therapeutic landscape within the United States.IBS-C is a condition that affects millions, leading to persistent discomfort, impaired quality of life, and considerable healthcare costs. The newly published review details the multifaceted challenges facing IBS-C patients, from the physical symptoms that dominate their daily lives to the psychological distress that often accompanies chronic gastrointestinal issues. As patient advocacy groups rally for more research and treatment options, Ardelyx’s commitment to filling this therapeutic void is timely and necessary.
Ardelyx, Inc. a biopharmaceutical company specializing in the development of innovative therapies for patients with gastrointestinal and kidney conditions, is currently navigating turbulent waters. Recent reports have highlighted significant financial challenges while also announcing a key deadline for investors involved in a class action lawsuit. The combination of a notable cumulative net loss and legal uncertainties prompts a thorough examination of Ardelyx’s current standing and future outlook. Investor Class Action Lawsuit On September 14, 2024, the Rosen Law Firm, a prominent player in global investor rights, informed investors of Ardelyx, Inc. who purchased securities between October 31, 2023, and July 1, 2024, of an upcoming deadline. Investors have been encouraged to secure legal counsel before the critical date of October 15, 2024, which marks the lead plaintiff deadline for a securities class action lawsuit.
Ardelyx, a biopharmaceutical company dedicated to developing groundbreaking medicines for unmet medical needs, has announced the appointment of Mike Kelliher as the Executive Vice President of Corporate Development and Strategy. With an extensive background in the biopharmaceutical industry, Kelliher brings invaluable expertise in mergers and acquisitions, business development, finance, and operational leadership from his tenure at prominent biotechnology and pharmaceutical companies. Details and Impact: - March 25, 2024: Ardelyx, Inc. reveals the addition of Mike Kelliher to their leadership team as the new EVP of Corporate Development and Strategy. - Kelliher possesses over 20 years of experience in the biopharmaceutical industry, consolidating his expertise in various critical areas. - This appointment reflects Ardelyx s commitment to securing top talent, further driving their mission to revolutionize patient care and meet unmet medical needs.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
